Funding for this research was provided by:
Göteborgs Läkaresällskap (GLS-590841, GLS-685801)
Received: 29 May 2019
Revised: 11 July 2019
Accepted: 22 July 2019
First Online: 1 August 2019
Ethics approval and consent to participate
: The study was approved by the local Animal Ethics Committee in Gothenburg, Sweden (permit no 89-2016, 131-2016, 22-2016).
: Not applicable.
: Jan Lötvall and Su Chul Jang have filed multiple patents for the development of EVs and EV-like nanovesicles for therapeutic purposes. Kyong-Su Park has filed several patents for using OMVs as sepsis model and vaccine, as well as investigating nanovesicle therapeutics. Jan Lötvall has previously been an employee of Codiak BioSciences Inc., and Su Chul Jang is currently employed by this company with the objective to develop EVs as therapeutics. The other authors declare that they have no competing interests.